Next Article in Journal
Polyamine Biosynthetic Pathway as a Drug Target for Osteosarcoma Therapy
Next Article in Special Issue
Lung Transplantation in Idiopathic Pulmonary Fibrosis
Previous Article in Journal
Care Bundles after Discharging Patients with Chronic Obstructive Pulmonary Disease Exacerbation from the Emergency Department
Previous Article in Special Issue
Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Med. Sci. 2018, 6(3), 64; https://doi.org/10.3390/medsci6030064

Cell Therapy in Idiopathic Pulmonary Fibrosis

1
Departamento de Patología Experimental, Instituto de Investigaciones Biomédicas de Barcelona IIBB-CSIC-IDIBAPS, Rosselló, 161, 08036 Barcelona, Spain
2
Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Melchor Fernández Almagro 3, 28029 Madrid, Spain
In memory of Antoni Xaubet. He was a great collaborator, a mentor but above all a good personal friend. I will miss him.
Received: 12 June 2018 / Revised: 2 August 2018 / Accepted: 8 August 2018 / Published: 13 August 2018
(This article belongs to the Special Issue Idiopathic Pulmonary Fibrosis)
Full-Text   |   PDF [2178 KB, uploaded 13 August 2018]   |  

Abstract

Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical studies. In this review, the current knowledge of these cell therapies is summarized. Although further investigations are required, these studies indicate that cell therapies are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis. View Full-Text
Keywords: cell therapy; stem cells; lung progenitor cells; preclinical studies; bleomycin; pulmonary fibrosis; clinical studies; idiopathic pulmonary fibrosis cell therapy; stem cells; lung progenitor cells; preclinical studies; bleomycin; pulmonary fibrosis; clinical studies; idiopathic pulmonary fibrosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Serrano-Mollar, A. Cell Therapy in Idiopathic Pulmonary Fibrosis. Med. Sci. 2018, 6, 64.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top